Robin K Kelley

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
    R K Kelley
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco UCSF, San Francisco
    Ann Oncol 24:1900-7. 2013
  2. ncbi request reprint Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012
  3. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
  4. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
  5. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
  6. doi request reprint Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013
  7. pmc Biomarker use in colorectal cancer therapy
    Robin K Kelley
    University of California, San Francisco, CA, USA
    J Natl Compr Canc Netw 9:1293-302. 2011

Detail Information

Publications7

  1. pmc Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
    R K Kelley
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco UCSF, San Francisco
    Ann Oncol 24:1900-7. 2013
    ....
  2. ncbi request reprint Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012
    ..A great need exists for comprehensive and dynamic practice guidelines for all types of biomarker testing according to tumor type...
  3. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
    ..Potential implications of this conclusion and future directions for research are discussed...
  4. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
    ..Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making...
  5. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  6. doi request reprint Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013
    ..Collectively, these and other new strategies are needed to make progress in identifying active novel therapeutics for patients with HCC...
  7. pmc Biomarker use in colorectal cancer therapy
    Robin K Kelley
    University of California, San Francisco, CA, USA
    J Natl Compr Canc Netw 9:1293-302. 2011
    ..A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed...